CytomX Therapeutics, Inc. - Common Stock (CTMX)

Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway.

CytomX Therapeutics reported promising Phase 1 expansion results for Varseta-M in late-line metastatic colorectal cancer.

CytomX Therapeutics Q3 2025 earnings miss analyst estimates for revenue and EPS, triggering a negative market reaction.

One pundit believes the company might have a winning cancer drug in its pipeline.

Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million.

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

CytomX Therapeutics (CTMX) Q2 2025 revenue beat estimates at $18.66M, with break-even EPS. Shares rose slightly as clinical progress, including CX-2051 data, boosts optimism.

CYTOMX THERAPEUTICS (CTMX) meets Minervini’s trend criteria with strong technicals and high-growth fundamentals, making it a candidate for momentum investors.